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Purpose: Amylin secretion is increased parallel to insulin in obese subjects. Despite 
their marked obesity, a state of relative hypoinsulinemia occurs in children with 
Prader-Willi syndrome (PWS). Based on the hypothesis that amylin levels may be 
relatively low in PWS children, contributing to their excessive appetite, we studied 
amylin levels after oral glucose loading in children with PWS and overweight con-
trols. Materials and Methods: Plasma levels of amylin, glucagon, insulin, and glu-
cose were measured at 0, 30, 60, 90, and 120 min after a glucose challenge in chil-
dren with PWS (n = 18) and overweight controls (n = 25); the relationships among 
the variables were investigated in these two groups. Results: Amylin levels were 
significantly correlated with insulin during fasting and during the oral glucose toler-
ance test in both groups. Amylin levels between 0 and 60 min after glucose loading 
were statistically different between the two groups. They were lower in children with 
PWS than in the controls between 0 and 30 min after glucose loading. Conclusion: 
The relatively low levels of amylin, compared to those in overweight controls, dur-
ing the early phase of glucose loading in patients with PWS, may contribute, in part, 
to the excessive appetite of PWS patients as compared to the overweight controls.
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INTRODUCTION
Prader-Willi syndrome (PWS) is the most common genetic cause of obesity; it is 
characterized by neonatal hypotonia, mental retardation, behavioral abnormalities, 
and excessive appetite with progressive massive obesity.1 Many studies have re-
cently attempted to evaluate the role of gut hormones in the regulation of food in-
take associated with obesity.2-4 We can gather that gut hormones represent an im-
portant potential pharmaceutical target for the treatment of obesity.
Amylin, a peptide and one of these gut hormones, is co-secreted with insulin 
postprandially by pancreatic β cells, reducing food intake and gastric emptying, 
and inhibiting pancreatic glucagon secretion and pancreatic and gastric enzyme se-Hae Jeong Lee, et al.
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middle schools located in southern Seoul. The purpose of 
the study was explained to the teachers, and a written study 
protocol was sent to all parents. The criteria for enrollment 
of the overweight controls included a BMI of higher than 
the 85th percentile for age and gender. For children with 
PWS, informed consent was obtained only from parents or 
guardians, and for the controls, it was obtained from both 
the study participants and their parents or guardians. Growth 
hormone therapy had been given to the children with PWS. 
None of the study subjects were receiving any medications 
besides growth hormone. The study design was reviewed 
and approved by the Samsung Medical Center Institutional 
Review Board.
Methods
Glucose in a dose of 1.75 g/kg body wt (up to a maximum 
of 75 g) was given orally the morning after a 10- to 12-h 
overnight fast, and blood samples were obtained to mea-
sure plasma glucose, insulin, glucagon, and amylin levels 
every 30 min over a 120 min period. The samples were col-
lected in ice-cooled EDTA tubes, centrifuged immediately, 
and stored at -70°C until further use.
Hormone measurements
Plasma glucose levels were detected by a YSI 2,300 dual 
analyzer (Yellow Springs Instrument Co., Yellow Springs, 
OH, USA). Serum insulin was determined by a commercial 
immunoradiometric assay kit (BioSource Europe S.A., 
Nivelles, Belgium) with a detection limit of 1 µU/mL and 
intra- and interassay coefficients of variation of less than 
10%. Plasma glucagon was measured by double antibody 
radioimmunoassay using a kit from Diagnostic Products 
cretion.2,5 Amylin has been reported to reduce food intake 
after peripheral or central administration.6 Despite their 
marked obesity, a state of relative hypoinsulinemia exists in 
children with PWS. Several studies have shown that fasting 
insulin concentrations are lower in children with PWS when 
compared with children matched for body mass index (BMI), 
and their insulin sensitivity is increased.7,8 Amylin secretion 
increases parallel with insulin in obese and insulin-resistant 
subjects.9 Therefore, amylin levels may be relatively low in 
children with PWS compared to the overweight controls; 
this may result in excessive appetite in PWS patients. This 
is the first study to compare plasma amylin levels after an 
oral glucose tolerance test (OGTT) in children with PWS to 
overweight controls. In addition, the responses of plasma 
amylin, serum insulin, and glucagon to glucose loading in 




Eighteen children with PWS (BMI 23.6 kg/m2, interquartile 
range, 20.8-26.9 kg/m2) and 25 overweight controls (BMI 
25.6 kg/m2, interquartile range, 24.0-28.2 kg/m2) were stud-
ied. Subjects with diabetes mellitus (fasting plasma glucose 
>126 mg/dL with a 2-h OGTT value of > 200 mg/dL) were 
excluded. The 18 patients with PWS were recruited from 
the pediatric outpatient clinics at Samsung Medical Center 
between July 2007 and January 2008. All subjects were pre-
pubertal; their clinical characteristics are listed in Table 1.
The controls were recruited from several elementary and 
Table 1. Characteristics of Study Subjects
PWS Overweight control p value
n 18 25
Age (yrs) 10 (9 - 13)  11 (9.5 - 12.5) 0.431
Male / female 9 / 9 6 / 19 0.077
BMI (kg/m
2) 23.6 (20.8 - 26.9) 25.6 (24.0 - 28.2) 0.085
BMI SD score 2.14 (1.31 - 4.52) 2.36 (1.67 - 3.46) 0.631
HOMA-IR   3.64 (2.81 - 76.09) 4.59 (3.57 - 6.83) 0.295
WBISI 2.06 (1.35 - 2.64) 1.79 (1.39 - 2.39) 0.453
Basal insulin (pmol/L) 113.6 (88.9 - 186.1)   132.0 (111.8 - 171.5) 0.424
WC (cm) 73.5 (71.5 - 89.0) 86.0 (78.0 - 90.0) 0.029
HiC (cm)   88.0 (83.0 - 102.0)   94.0 (88.0 - 101.0) 0.112
WC to HiC ratio 0.88 (0.84 - 0.88) 0.91 (0.86 - 0.93) 0.054
PWS, Prader-Willi syndrome; BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; WBISI, whole-
body insulin sensitivity index; WC, waist circumference; HiC, hip circumference.
Results are expressed as median and interquartile ranges. Amylin Levels after an Oral Glucose Challenge
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Corp. (DPC)(Los Angeles, CA, USA). Plasma amylin mea-
sured in duplicate using a commercially abailable ELISA kit 
(Linco Research, Inc., St. Charles, MO, USA); inter- and in-
traassay coefficient of variance were less than 10%, and the 
assay sensitivities were ranged from 4.85 to 83.90 pg/mL, 
respectively. The antibody does not cross-react with insulin 
and other known gastrointestinal hormones.
Statistical analysis
Insulin sensitivity indexes were determined by homeostasis 
model assessment for insulin resistance (HOMA-IR) and 
the whole-body insulin sensitivity index (WBISI). WBISI 
was calculated using OGTT, as proposed by Matsuda and 
DeFronzo, as 10,000/√ (fasting glucose × fasting insulin) × 
(mean glucose × mean insulin during OGTT). 
All values are presented as the median and interquartile 
ranges in the tables and as mean ± SE in the figures. The t-
test with Bonferroni’s correction was used to analyze nor-
mally distributed data; in other cases, the Mann-Whitney U 
test with Bonferroni’s correction and the Wilcoxon test were 
used to compare the hormone levels between the children 
with PWS and the controls.
Changes in hormone levels over time for the two groups 
were tested using two-way repeated-measures analysis of vari-
ance (ANOVA). Correlations were determined using Spear-
man’s correlation analysis; p values of < 0.05 were considered 
statistically significant. All statistical analyses were performed 
using SAS version 8.2 (SAS Corp., Cary, NC, USA).
RESULTS
Comparison of the plasma glucose, insulin, glucagon, 
and amylin levels of the PWS and control groups
A summary of the clinical characteristics of the study sub-
jects is listed in Table 1. Simple comparisons of fasting glu-
cose, insulin, glucagon, and amylin levels of the PWS chil-
dren and the controls were not significantly different, and 
neither were the plasma glucose, insulin, glucagon, and amy-
lin levels at any point in time during the OGTT (Fig. 1). 
However, repeated-measures ANOVA showed a signifi-
cant amylin × time interaction, showing that changes in amy-
lin over time were significantly different for the two groups 
(p = 0.0154)(Fig. 1B). The amylin levels between 0 and 60 
min after glucose loading were statistically different in the 
two groups (p = 0.0076)(Fig. 1B). The amylin levels be-
tween 0 and 30 min after glucose loading were lower in the 
children with PWS than in the controls. However, 60 min af-
ter glucose loading, the amylin levels were higher in the chil-
dren with PWS than in the controls (Fig. 1B). Therefore, a 
Fig. 1. Changes in plasma insulin, amylin, glucose, and glucagon levels after the glucose challenge. Repeated-measures ANOVA showed 
a significant amylin × time interaction, indicating that changes in amylin over time were significantly different between the two study 
groups (*p = 0.0154). Amylin levels between 0 and 60 min after glucose loading were statistically different between the two groups (†p = 
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Amylin and glucose levels showed a correlation at 0 min 
only in the control group (r = 0.559, p = 0.0222). Amylin lev-
els were found to correlate with the glucagon levels at 60 
min only in the PWS children group (r = 0.6667, p = 0.0150) 
(Fig. 3). No correlation was observed between the AUC of 
amylin and the AUC of glucagon (PWS: r = 0.6009, p = 
0.0504; control: r = -0.1400, p = 1.0) or the AUC of amylin 
and the AUC of glucose (PWS: r = 0.3891, p = 0.6630; 
control: r = 0.2731, p = 1.0) in either group.
Insulin sensitivity index vs. amylin
A correlation was found between the insulin sensitivity index 
and amylin. Amylin levels were compared with the HOMA-
IR, and a positive correlation was observed at 0 min in both 
groups (Fig. 4). Amylin levels and WBISI showed a negative 
correlation at 30 min (r = - 0.6553, p = 0.0160) and 90 min (r 
= - 0.5975, p = 0.0440) after the glucose challenge in the 
PWS group, and at 0 min (r = - 0.6931, p = 0.0005), 30 min 
(r = - 0.6392, p = 0.0030), 60 min (r = - 0.8600, p = 0.0005), 
90 min (r = - 0.6339, p = 0.0035) and 120 min (r = - 0.5639, 
p = 0.0165) in the control group.
delayed response of amylin in PWS children was likely re-
sponsible for the significant amylin × time interaction com-
pared to the controls. 
When the two groups were compared with regard to am-
ylin/insulin ratios, no significant difference was observed at 
any point in time during the OGTT (Fig. 2).
Correlation among plasma glucose, insulin, glucagon, 
and amylin levels
Amylin and insulin levels showed a correlation at 0 min 
(control: r = 0.7805, p = 0.0006; PWS: r = 0.7393, p = 
0.0030), 30 min (control: r = 0.8262, p = 0.0006; PWS: r = 
0.8762, p = 0.0006), 60 min (control: r = 0.7577, p = 0.0006; 
PWS: r = 0.8349, p = 0.0006), 90 min (control: r = 0.6644, p 
= 0.0018; PWS: r = 0.7338, p = 0.0030), and 120 min (con-
trol: r = 0.7162, p = 0.0006; PWS: r = 0.6574, p = 0.0180) af-
ter glucose loading in both the control and the PWS groups. 
When the area under the curve (AUC) of amylin was com-
pared with the AUC of insulin, a positive correlation was ob-
served between the two groups (control: r = 0.7269, p = 
0.0006; PWS: r = 0.8225, p = 0.0006).
Fig. 2. No significant differences in the amylin/insulin molar ratio were ob-







































Fig. 3. Relationships between glucagon and amylin levels. Amylin levels at 
60 min after glucose loading were found to be correlated with glucagon 
levels at 60 min in the children with Prader-Willi syndrome (r=0.6667, p = 
0.0150).




























r = 0.6667, p = 0.0150
Fig. 4. HOMA-IR had a positive correlation with fasting amylin levels in both study groups (PWS: r = 0.6966, p = 0.0065; control r = 0.7885, p = 
0.0005). HOMA-IR, homeostasis model assessment for insulin resistance; PWS, Prader-Willi syndrome.
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Ludvik, et al.16 reported a significant correlation between 
changes in amylin secretion and the suppression of gluca-
gon secretion following oral glucose ingestion in healthy 
and diabetic human subjects. In this study, amylin levels 
were positively correlated with glucagon at 60 min after 
glucose loading in children with PWS only (Fig. 3). There-
fore, amylin might not contribute to postprandial glucagon 
suppression in children with PWS.
Insulin resistance is a common feature of childhood obe-
sity. Elevated insulin levels due to insulin resistance might 
be associated with an increase in amylin concentrations in 
childhood obesity.17 The results of this study showed that 
fasting amylin levels were correlated with HOMA-IR in 
both groups (Fig. 4). Amylin levels and WBISI showed a 
negative correlation at 30 min and 90 min after the glucose 
challenge in the children with PWS and at 0 min, 30 min, 
60 min, 90 min, and 120 min in the control group. The reg-
ulation of amylin was closely related to insulin sensitivity 
in both study groups.
In conclusion, the results of this study suggest a delayed 
increase in amylin levels post oral glucose challenge in 
children with the PWS. The relatively low levels of amylin, 
compared to the overweight controls, during the early phase 
of the glucose loading test in PWS, may contribute, in part, 
to the excessive appetite of children with PWS as compared 
to the overweight control population.
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